Mirum Pharmaceuticals Inc
MIRMHealthcare|Biotechnology|USA
$122.13
-5.67 (-4.44%)
Financials
Financial Snapshot
Market Cap
$7.45B
Enterprise Value
$62.5M
Revenue (TTM)
$569.6M
Net Income (TTM)
$-798.8M
Cash & Equivalents
—
Net Cash/Share
$-4.30
Free Cash Flow (TTM)
$-182.6M
Operating CF (TTM)
$-171.0M
Debt/Equity
1.34
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$42.7M
Monthly Burn
$14.2M
Est. Runway
—
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $52.0M | $116.7M | $231.8M | $156.5M | $151.7M | $286.3M | $280.3M | $383.3M | $386.3M | |
| Operating Cash Flow | $0.00 | $-39.4M | $-89.1M | $-132.8M | $-120.1M | $-70.9M | $10.3M | $55.8M | $-171.0M | |
| Free Cash Flow | $0.00 | $-39.6M | $-89.3M | $-151.8M | $-120.4M | $-91.1M | $-10.7M | $54.9M | $-182.6M | |
| Capital Expenditure | $0.00 | $-281.0K | $-225.0K | $-19.0M | $-278.0K | $-20.1M | $-21.0M | $-954.0K | $-11.6M | |
| Financing Cash Flow | $0.00 | $127.2M | $181.3M | $73.5M | $109.1M | $336.6M | $17.7M | $40.1M | $303.9M |
R&D Spending
R&D (TTM)
$238.0M
R&D Intensity
41.8%
R&D Growth YoY
+27.9%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M | $569.6M | |
| R&D Expense | $0.00 | $43.0M | $81.6M | $131.4M | $106.8M | $102.6M | $140.6M | $186.2M | $238.0M | |
| R&D % of Revenue | — | — | — | 686.7% | 138.6% | 55.1% | 41.7% | 35.7% | 41.8% | |
| SG&A | $0.00 | $11.8M | $22.7M | $59.2M | $89.1M | $145.9M | $202.2M | $257.0M | $295.7M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $19.1M | $77.1M | $186.4M | $336.9M | $521.3M | $569.6M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $1.9M | $12.4M | $47.0M | $81.6M | $100.2M | $106.0M | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $17.2M | $64.7M | $139.3M | $255.2M | $421.1M | $463.6M | |
| R&D | $0.00 | $43.0M | $81.6M | $131.4M | $106.8M | $102.6M | $140.6M | $186.2M | $238.0M | |
| SG&A | $0.00 | $11.8M | $22.7M | $59.2M | $89.1M | $145.9M | $202.2M | $257.0M | $295.7M | |
| Operating Income | $0.00 | $-54.7M | $-104.3M | $-173.4M | $-131.2M | $-109.2M | $-87.6M | $-22.1M | $-70.1M | |
| Interest Expense | $0.00 | $0.00 | $-335.0K | $-17.6M | $-16.0M | $-15.1M | $-14.3M | $-14.4M | $-14.4M | |
| Pretax Income | $0.00 | $-52.5M | $-103.3M | $-84.0M | $-142.1M | $-162.4M | $-86.9M | $-21.4M | $-797.5M | |
| Net Income | $0.00 | $-52.6M | $-103.3M | $-84.0M | $-135.7M | $-163.4M | $-87.9M | $-23.4M | $-798.8M | |
| EPS (Diluted) | 0.00 | -4.58 | -4.09 | -2.77 | -4.02 | -4.00 | -1.85 | -0.47 | -13.61 | |
| EBITDA | $0.00 | $-52.2M | $-102.3M | $-65.8M | $-122.9M | $-136.5M | $-49.0M | $17.2M | $-758.0M | |
| Shares Out. (M) | - | 11.49 | 25.25 | 30.32 | 33.98 | 40.88 | 47.52 | 50.20 | 58.85 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.0M | $12.0M | $142.1M | $31.3M | $28.0M | $286.3M | $222.5M | $296.7M | $324.9M | |
| Marketable Securities | $0.00 | $104.7M | $89.7M | $125.2M | $123.7M | $0.00 | $57.8M | $86.6M | $61.4M | |
| Total Current Assets | $52.0M | $119.4M | $236.3M | $166.6M | $190.2M | $387.5M | $392.8M | $549.7M | $569.4M | |
| Total Assets | $52.0M | $146.7M | $240.9M | $294.7M | $352.9M | $646.6M | $670.8M | $842.8M | $890.9M | |
| Total Current Liabilities | $2.4M | $13.1M | $18.5M | $42.6M | $64.7M | $87.1M | $126.6M | $205.8M | $272.8M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $306.4M | $308.1M | $309.8M | $310.3M | |
| Total Liabilities | $62.3M | $16.4M | $68.8M | $174.4M | $210.9M | $398.0M | $445.1M | $528.1M | $648.4M | |
| Stockholders' Equity | $-10.3M | $130.3M | $172.1M | $120.2M | $142.0M | $248.7M | $225.6M | $314.7M | $242.5M | |
| Retained Earnings | $-17.3M | $-69.9M | $-173.2M | $-257.2M | $-392.8M | $-556.2M | $-644.2M | $-667.5M | $-1.46B |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $-39.4M | $-89.1M | $-132.8M | $-120.1M | $-70.9M | $10.3M | $55.8M | $-171.0M | |
| Capital Expenditure | $0.00 | $-281.0K | $-225.0K | $-19.0M | $-278.0K | $-20.1M | $-21.0M | $-954.0K | $-11.6M | |
| Free Cash Flow | $0.00 | $-39.6M | $-89.3M | $-151.8M | $-120.4M | $-91.1M | $-10.7M | $54.9M | $-182.6M | |
| Investing Cash Flow | $0.00 | $-127.8M | $37.9M | $48.5M | $7.7M | $-107.2M | $-90.1M | $-24.0M | $-19.4M | |
| Financing Cash Flow | $0.00 | $127.2M | $181.3M | $73.5M | $109.1M | $336.6M | $17.7M | $40.1M | $303.9M | |
| Issuance of Stock | $0.00 | $67.2M | $131.9M | $6.9M | $107.4M | $216.7M | $0.00 | $0.00 | $259.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $305.3M | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $6.1M | $12.6M | $23.1M | $27.0M | $35.0M | $48.4M | $71.4M | $91.8M | |
| Net Change in Cash | $0.00 | $-40.0M | $130.1M | $-10.7M | $-3.3M | $158.3M | $-63.4M | $75.2M | $114.4M |
Dilution Tracker
Shares outstanding grew 94.1% over 5 years — significant dilution
Shares Outstanding
59M
5-Year Share Growth
+94.1%
Stock Issuance (TTM)
$259.9M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | - | 11.49 | 25.25 | 30.32 | 33.98 | 40.88 | 47.52 | 50.20 | 58.85 | |
| YoY Change % | — | — | 119.9% | 20.1% | 12.1% | 20.3% | 16.2% | 5.6% | 17.2% | |
| Stock Issuance | $0.00 | $67.2M | $131.9M | $6.9M | $107.4M | $216.7M | $0.00 | $0.00 | $259.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $6.1M | $12.6M | $23.1M | $27.0M | $35.0M | $48.4M | $71.4M | $91.8M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 90.1% | 83.9% | 74.8% | 75.8% | 80.8% | 81.4% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% | -12.3% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% | -140.2% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | -343.6% | -159.4% | -73.2% | -14.5% | 3.3% | -133.1% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | -793.1% | -156.3% | -48.9% | -3.2% | 10.5% | -32.0% | |
| ROE % | 0.0% | -87.6% | -68.3% | -57.5% | -103.5% | -83.7% | -37.1% | -8.6% | -298.6% | |
| ROA % | 0.0% | -52.9% | -53.3% | -31.4% | -41.9% | -32.7% | -13.4% | -3.1% | -101.5% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S11.62
Historical4.66 / 8.81 / 50.94
Industry Med.9.51
P/B30.69
Historical3.95 / 7.99 / 31.56
Industry Med.2.93
EV/EBITDA-9.74
Historical-1996.67 / -9.48 / 311.16
Industry Med.13.14
EV/Revenue12.97
Historical5.01 / 8.76 / 30.81
Industry Med.8.71
P/FCF—
Historical78.23 / 91.83 / 105.37
Industry Med.27.54
Intrinsic Value Models
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | 25.28 | 8.60 | 6.48 | 5.83 | 7.61 | 11.62 | |
| PB Ratio | 0.00 | 4.25 | 3.02 | 4.06 | 5.07 | 5.55 | 8.86 | 13.03 | 30.69 | |
| EV/EBITDA | 0.00 | -8.45 | -2.85 | -5.08 | -4.65 | -10.27 | -41.58 | 234.53 | -9.74 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 17.45 | 7.41 | 7.52 | 6.04 | 7.74 | 12.97 |
Analyst Estimates & Quality
Altman Z-Score
2.74
Grey Zone
Piotroski F-Score
4
Moderate
Beneish M-Score
-1.64
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $675.3M | $815.2M | $1,063.9M |
| Net Income | $-915.4M | $-13.0M | $168.3M |
| EPS | -15.61 | -0.90 | 2.16 |
| Book Value per Share | 0.22 | 2.79 | 7.03 |
| Operating Cash Flow per Share | -3.55 | 1.42 | 3.99 |
| Operating CF | $-208.92M | $83.57M | $234.82M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Product sales, net | $521.3M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $401.5M |
| Rest of the world | $119.8M |